Ceva Animal Health is restructuring its top leadership as it prepares for its next phase of growth, appointing Sébastien Huron as Deputy Chief Executive Officer and transitioning to a dual governance model.

Under the new structure, CEO Marc Prikazsky will move into the role of Executive Chairman, focusing on long-term strategy, investor engagement, and innovation, while Huron takes charge of day-to-day operations and chairs the Executive Committee.

A Governance Shift for Scale

The leadership transition reflects Ceva’s evolution into one of the world’s largest animal health companies, as it seeks to sharpen both strategic oversight and operational execution. The dual structure is designed to separate long-term vision from execution—an approach increasingly adopted by global companies navigating complex growth environments.

A Global Operator at the Helm

Sébastien Huron brings more than three decades of international experience across animal health and allied sectors, with leadership roles spanning Europe, the Americas, and emerging markets.

His career includes senior positions at Mars Inc., RousselUclaf, Hoechst Roussel Vet, Intervet, and Virbac, where he served as CEO from 2017 to 2024, overseeing a period of sustained organic growth.

With a background in veterinary science and experience across marketing, R&D, and global operations, Huron is positioned to drive execution across Ceva’s expanding portfolio.

Strategic Continuity, Operational Acceleration

The shift allows Prikazsky to focus on Ceva’s long-term priorities, including strengthening investor relationships, advancing customer-focused innovation, and building leadership pipelines, while Huron leads operational delivery and global business performance.

The move comes as the animal health sector undergoes structural change—driven by rising demand for protein, increasing focus on sustainability, and rapid innovation in vaccines, biologics, and precision animal health.

Positioning for the Next Growth Phase

Ceva, majority-owned by its management, has built a reputation for entrepreneurial agility in a sector dominated by large multinationals. The leadership transition signals an intent to scale that model while maintaining strategic clarity and execution discipline.

As competition intensifies and global demand for animal health solutions grows, the company’s ability to balance long-term innovation with operational excellence will be central to its next phase of expansion.